Enjoy complimentary customisation on priority with our Enterprise License!
The Cell Therapy Market size is estimated to grow by USD 84.58 billion at a CAGR of 73.89% between 2023 and 2028. The limitations of traditional organ transplantation, coupled with challenges such as organ shortages, the risk of rejection, and long waiting times, have heightened the need for alternative solutions. This urgency has led to a growing demand for cell therapies, particularly in areas where traditional treatments have been inadequate, such as in the case of cataracts and neurological conditions. In response to these challenges, there has been a substantial increase in funding for cell-based research, which is accelerating advancements in this field. This surge in investment is driving innovation and the development of new therapies that aim to address these complex issues. Among the most promising advancements is CAR T-cell therapy, which has shown remarkable effectiveness in treating certain cancers. By genetically modifying a patient's own T-cells to better target and destroy cancer cells, CAR T-cell therapy provides a powerful new option where conventional treatments have often been insufficient. It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018 to 2022, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
The autologous segment is estimated to witness significant growth during the forecast period. There is only a moderate growth of the autologous cell therapy segment due to its manufacturing complexities. Additionally, there is a low preference for this cell therapy in emergency care as it needs more time to generate autologous therapy cells.
Get a glance at the market contribution of various segments View a PDF Sample
The autologous segment was the largest segment and was valued at USD 690.40 million in 2018. Factors such as global population growth, climate change, and virus outbreaks fuel the need for advanced cell therapies. Key players like Thermo Fisher Scientific, Merck KGaA, Lonza, and Danaher dominate the market, focusing on cell processing, cell preservation, process monitoring, quality control, and cell banking facilities. Precision medicine and individual differences necessitate extensive research in cell biology and disease mechanisms, driving the development of new products and the entry of small players. Regulatory guidelines and quality standards ensure survival and safety in oncology applications. Companies invest in funding and adhere to guidelines for cell banking, storage, and clinical trials, including EU grants, to advance treatment responses. Achilles Therapeutics is an example of a company pioneering innovative cell types in the field. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the market during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Some of the main factors that are significantly contributing to the growth of the global market in North America are increased funding from governments and the growing number of regenerative medicine centers in the region, especially in countries such as the US, Canada, and Mexico.
Moreover, one of the prominent markets in North America for the growth of the global market is the US due to the increased funding offered by the government departments including NH and the Biomedical Advanced Research and Development Authority (BARDA) to small-scale industries and companies that are focusing on developing novel products. Hence, such factors are expected to drive market in the region during the forecast period.
Buy Now Full Report and Discover More
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Astellas Pharma Inc: The company offers ASP7317 for the treatment of dry AMD.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The Diseseas Mechanisms and Treatment Foundation (DMTF) reports that the Cell Therapy market is experiencing significant growth, driven by advances in technology and research. Producers of cell therapies, such as Diseseas Mechanisms and Treatment (Disease), are developing new methods for the production and delivery of these therapies. For instance, Diseaseas is utilizing its proprietary technology to create a population of functional cells for use in cell therapy. The global Cell Therapy market is expected to grow considerably, with a focus on areas like gene therapy, cellular immunotherapy, and regenerative medicine. The use of cell therapies in these areas is revolutionizing the treatment of various diseases, including cancer and neurological disorders. The Climate, Cell, and Life Sciences Alliance (C-CSLA) and the Guideline Implementation Network (G-IN) are also playing crucial roles in the progress of cell therapy research and development. The market includes various types of cell therapies such as Stem Cell Therapies, Immunotherapies, and Gene Therapies. The treatment of various diseases, such as types and research, is a key focus of the Cell Therapy market. Virus-based outbreaks, such as COVID-19, have further highlighted the importance of cell therapies in the development of effective treatments.
One of the key factors driving the market growth is the proven effectiveness of CAR T-cell therapy. There is an increasing preference for VAR-T cell therapies as it tends to have high efficacy when compared to other therapies that exist in the market for the treatment of cancer. The market is experiencing significant growth due to the limitations and risks associated with conventional organ transplantation. With the increasing demand for kidney transplants, accounting for over 80% of the total transplants in 2020, the need for alternative solutions is paramount. Horizon Europe is investing in personalized medicine, including stem cell therapy, to address chronic conditions such as insulin-dependent diabetes. Companies like Sernova and Evotec are pioneering the use of adult stem cells and cord blood processing to develop novel therapeutic regimes.
Furthermore, new therapeutic regimes, such as ALLO-501, are under development to address these challenges. In summary, the cell therapy market is growing due to the limitations of conventional organ transplantation and the potential of personalized medicine and stem cell therapy to address chronic conditions and regenerative medicine. Companies are investing in automation, genetic editing tools, and collaborations to develop novel therapeutic regimes for various indications, including oncology and musculoskeletal disorders. Challenges remain, but ongoing research and clinical studies are addressing these issues. Hence, such factors are positively impacting the market which, in turn, will drive the market growth during the forecast period.
A key factor shaping the market growth is the rise in vaccine production. There is increasing adoption of vaccines as it helps in the prevention of infectious diseases including diphtheria, hepatitis B, and measles. Vaccines are considered one of the cost-effective and successful strategies for precaution against health. The market encompasses various types of cells, including progenitor cells, adult and embryonic stem cells, and iPS cells, which have shown effectiveness in treating chronic conditions such as heart failure, cancer, and diabetes. The European Union's Horizon Europe initiative supports research in personalized medicine, including stem cell therapy. Sernova and Evotec are key players in insulin-dependent diabetes research using adult stem cells and cord blood processing.
Moreover, research institutes and pharmaceutical giants, such as Panacell Biotech and Cellino Biotech, are collaborating on clinical studies for musculoskeletal disorders and pneumonia treatments. Pharmaceutical and biotechnology companies are exploring novel therapeutic regimes in regenerative medicine for chronic conditions. As a result, there is a constant requirement for cell therapies for the regular supply of the same cell that can produce high-quality vaccines. Hence, such factors are positively impacting the market which in turn will drive the market growth during the forecast period.
High cost and failure rates in clinical trials are the key challenges hindering market growth. Several market players in developed countries, such as the US, the UK, Germany, France, Japan, Singapore, and South Korea, are conducting clinical trials of cell therapy products. The cost of clinical trials is high in these regions as these are high-income countries. The market encompasses advanced treatments like stem cell therapy and personalized medicine. European initiatives, such as Horizon Europe, support research in this sector. Notable companies, including Sernova and Evotec, focus on insulin-dependent diabetes using adult stem cells and cord blood processing. New technologies like automation, genetic editing tools such as CRISPR-Cas9, and allogeneic therapies are driving innovation. Regulatory bodies like the EMA and FDA oversee approvals for autologous therapy segment, CAR-T therapies, and novel therapeutic regimes for genetic disorders.
Moreover, several market players as well as startup biotech companies are increasingly relying on government or private funding. However, several organizations offer limited funds to market players till the target goal is completed. Hence, such constraints are negatively impacting the market which in turn will hinder the market growth during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.
The market refers to the growing industry of research, development, and application of cell-based therapies. These therapies utilize living cells to treat or prevent diseases and injuries. The Clinical Trials sector plays a crucial role in the Cell Therapy Market, as new treatments are continually being researched and developed. The market is also driven by the increasing demand for personalized treatments and the advances in technology that make cell therapies more effective and accessible. Achilles Therapeutics and Horizon Therapeutics are some of the key players in the market, focusing on various therapeutic areas such as Oncology and Rare Diseases. The market is expected to grow significantly in the coming years due to the potential benefits of these innovative therapies. The regulatory environment, particularly in the US and Europe, is also evolving to support the development and commercialization of cell therapies.
Moreover, the market is witnessing rapid growth, driven by advancements in Stem cell technologies and the development of novel Cell therapy approaches. Companies like Achilles Therapeutics and Calidi Biotherapeutics Inc. are pioneering Allogeneic cell therapy and exploring new Therapeutic regimes for various applications including Musculoskeletal, Malignancies, and Cardiovascular conditions. Key players like Bristol-Myers Squibb are leading the market with innovative products such as Breyanzi and Yescarta CAR T-cell therapy, which target CD19 and demonstrate the potential of CAR-T therapies. The market is also witnessing growth in Allogeneic Therapies Segment with the rise of Allogeneic Therapies.
Further, the market is advancing rapidly, driven by breakthroughs in cell biology research and the therapeutic potential of newborn stem cells, including umbilical cord blood and cord blood cells. These therapies show promise in treating diseases like acute lymphocytic leukemia, Type 1 Diabetes (T1D), and multiple myeloma. The oncology segment is particularly notable, with ongoing research supported by cell banks and the Food and Drug Administration (FDA). Immunosuppressive therapies and immune response modulation are crucial for successful treatment outcomes. Stem Cell Research & Therapy is evolving, with a focus on optimizing drug selection and harnessing the potential of cord cells and tissues for innovative treatments.
Market Scope |
|
Report Coverage |
Details |
Page number |
166 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 73.89% |
Market growth 2023-2028 |
USD 84.58 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
60.7 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Astellas Pharma Inc., Athersys Inc., Avita Medical Inc., BioCardia Inc., BioSenic SA, Brainstorm Cell Therapeutics Inc., Bristol Myers Squibb Co., Capricor Therapeutics Inc., Castle Creek Biosciences Inc., CellSeed Inc., Cellular Biomedicine Group Inc., Celyad Oncology SA, Gilead Sciences Inc., Lineage Cell Therapeutics Inc., Lisata Therapeutics Inc., Mesoblast Ltd., Novartis AG, Pharmicell Co. Ltd., Sanpower Group Co. Ltd., and ThermoGenesis Holdings Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.